The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the European Commission has approved the expanded use of Enhertu ...

Daiichi Sankyo Company, Limited leads in ADC tech with Enhertu, strong partnerships, revenue growth, and global market leadership. Click to know more on why DSNKY is a Buy.

In the DESTINY-Breast03 trial, Enhertu (trastuzumab deruxtecan) reduced the risk of disease progression or death compared to Kadcyla (trastuzumab emtansine) by 72% in patients with HER2-positive ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Enhertu’s parts and active ingredients are: An antibody (with the ingredient fam-trastuzumab): This part ... Chemotherapy (with the ingredient deruxtecan-nxki): This part of the drug hinders ...

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody ...

(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...

The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a single agent to treat adults with unresectable or metastatic hormone ...

The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with a fluoropyrimidine chemotherapy (5-FU or capecitabine ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU ® (trastuzumab deruxtecan) in combination with a ...